Vogt-Koyanagi-Harada Disease

References

• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retin Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Van Damme J, Struyf S, Opdenakker G. New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease. Front Med (Lausanne). 2021;8:705796. doi:10.3389/fmed.2021.705796.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr, Tugal-Tutkun I, Abu-El-Asrar A, Gupta A, Takeuchi M, Fardeau C, et al. Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review. Eye (Lond). 2022;36(1):29–43. doi:10.1038/s41433-021-01573-3.
   PubMed Web of Science ®Google Scholar
• Urzua CA, Herbort CJ, Valenzuela RA, Abu El-Asrar AM, Arellanes-Garcia L, Schlaen A, et al. Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2020;10(1):23. doi:10.1186/s12348-020-00214-2.
   PubMed Web of Science ®Google Scholar
• Papasavvas I, Tugal-Tutkun I, Herbort CP Jr. Vogt–Koyanagi–Harada is a curable autoimmune disease: early diagnosis and immediate dual steroidal and non-steroidal immunosuppression are crucial prerequisites. J Curr Ophthalmol. 2020;32:310–314. doi:10.4103/JOCO.JOCO_190_20.
   PubMed Web of Science ®Google Scholar
• Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature11The authors constitute the International Committee on Vogt-Koyanagi-Harada disease nomenclature, representing the participants of the First International Workshop on Vogt-Koyanagi-Harada disease. A full list of participants appears at the end of the article. Am J Ophthalmol. 2001;131(5):647–652. doi:10.1016/S0002-9394(01)00925-4.
   PubMed Web of Science ®Google Scholar
• Yang P, Zhong Y, Du L, Chi W, Chen L, Zhang R, et al. Development and evaluation of diagnostic criteria for Vogt-Koyanagi-Harada disease. JAMA Ophthalmol. 2018;136(9):1025–1031. doi:10.1001/jamaophthalmol.2018.2664.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2021;228:205–211. doi:10.1016/j.ajo.2021.03.036.
   PubMed Web of Science ®Google Scholar
• Snyder DA, Tessler HH. Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol. 1980;90:69–75. doi:10.1016/S0002-9394(14)75078-0.
   PubMed Web of Science ®Google Scholar
• Wu J, Pang S, Guo X, Peng W, Lin D, Dai M, et al. Comparison of the three sets of diagnostic criteria for Vogt-Koyanagi-Harada disease in Southeast China - a retrospective case-control study. Ocul Immunol Inflamm. 2022;32(4):376–383. doi:10.1080/09273948.2022.2146592.
   Web of Science ®Google Scholar
• Hedayatfar A, Khochtali S, Khairallah M, Takeuchi M, El Asrar AA, Herbort CP Jr. “Revised diagnostic criteria” for Vogt-Koyanagi-Harada disease fail to improve disease management. J Curr Ophthalmol. 2018;31(1):1–7. doi: 10.1016/j.joco.2018.10.011.
   PubMed Web of Science ®Google Scholar
• Ding X, Shu Q, Bai X, Chang Q, Xu G, Chen L. The role of widefield optical coherence tomography angiography in the diagnosis and management of acute Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2023;32(4):391–401. doi:10.1080/09273948.2023.2181186.
   Web of Science ®Google Scholar
• Ben Aoun S, Ksiaa I, Nefzi D, Khochtali S, Jelliti B, Abroug N, et al. SS OCT and OCT-A findings in convalescent inactive Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2023;32(4):407–414. doi:10.1080/09273948.2023.2274962.
   PubMed Web of Science ®Google Scholar
• Aggarwal K, Agarwal A, Mahajan S, Invernizzi A, Mandadi SKR, Singh R, et al. The role of optical coherence tomography angiography in the diagnosis and management of acute Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2018;26(1):142–153. doi:10.1080/09273948.2016.1195001.
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Charcán I, Giralt L, Artaraz J, Soto A, Ruiz-Arruza I, et al. Hyper-reflective outer nuclear layer (HONL) in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ocul Immunol Inflamm. 2022;32(4):419–423. doi:10.1080/09273948.2022.2134038.
   Web of Science ®Google Scholar
• Ali N, Thotathil A, Niederer R. Letter to the Editor: comment on fonollosa et al.‘s “Hyper-reflective outer nuclear layer (HONL) in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia”. Ocul Immunol Inflamm. 2023;32(4):437–439. doi:10.1080/09273948.2023.2217919.
   PubMed Web of Science ®Google Scholar
• Papasavvas I, Tugal-Tutkun I, Herbort CP Jr. Vogt-Koyanagi-Harada is a curable autoimmune disease: early diagnosis and immediate dual steroidal and non-steroidal immunosuppression are crucial prerequisites. J Curr Ophthalmol. 2020;32(4):310–314. doi:10.4103/JOCO.JOCO_190_20.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Rashed FA, AlBloushi AF, Tobaigy MF, Gikandi PW, Herbort CP Jr, et al. Therapeutic window of opportunity in the acute uveitic phase of Vogt-Koyanagi-Harada disease: prevention of late autoimmune complications by early intervention. Acta Ophthalmol. 2023;101(2):e236–e245. doi:10.1111/aos.15254.
   PubMed Web of Science ®Google Scholar
• Fauquier A, Barba T, Hot A, Sève P, Elbany S, Blanche P, et al. Impact of initial management on disease evolution in Vogt-Koyanagi-Harada syndrome: a retrospective cohort of 50 patients. Ocul Immunol Inflamm. 2023;32(4):402–406. doi:10.1080/09273948.2023.2206485.
   PubMed Web of Science ®Google Scholar
• Khairallah M, Khochtali S, Abroug N, Ksiaa I. Letter to the Editor: comment on fauquier a et al “Impact of initial management on disease evolution in Vogt-Koyanagi-Harada syndrome: a retrospective cohort of 50 patients”. Ocul Immunol Inflamm. 2023;32(4):440–441. doi:10.1080/09273948.2023.2227259.
   Web of Science ®Google Scholar
• Nakai S, Takeuchi M, Usui Y, Namba K, Suzuki K, Harada Y, et al. Efficacy and safety of adalimumab for exacerbation or relapse of ocular inflammation in patients with Vogt-Koyanagi-Harada disease: a multicenter study. Ocular Immunol Inflamm. 2022;32(4):367–375. doi:10.1080/09273948.2022.2092007.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dheyab A, Khatib D, Struyf S, Van Damme J, Opdenakker G. Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada Disease. Ocul Immunol Inflamm. 2022;30(3):750–757. doi:10.1080/09273948.2020.1820531.
   PubMed Web of Science ®Google Scholar
• Bolletta E, Gozzi F, Mastrofilippo V, Pipitone N, De Simone L, Croci S, et al. Efficacy of rituximab treatment in Vogt-Koyanagi-Harada disease poorly controlled by traditional immunosuppressive treatment. Ocul Immunol Inflamm. 2022;30(6):1303–1308. doi:10.1080/09273948.2021.1880604.
   PubMed Web of Science ®Google Scholar
• Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2011;1(4):177–180. doi:10.1007/s12348-011-0027-9.
   PubMedGoogle Scholar
• Souto FMS, Missaka RFBG, Lavezzo MM, Nóbrega PFC, Sakata VM, Oyamada MK, et al. Quality of life (QoL) in non-acute Vogt-Koyanagi-Harada disease (VKHD) at two time points 24 months apart. Ocul Immunol Inflamm. 2023;32(4):384–390. doi:10.1080/09273948.2022.2152697.
   Web of Science ®Google Scholar
• Kumar Menia N, Bansal R, Gupta V. Retrolental bullous retinal detachment as the presenting feature of Vogt-Koyanagi-Harada disease in an elderly Indian female: diagnostic and therapeutic challenge. Ocul Immunol Inflamm. 2023;32(4):429–432. doi:10.1080/09273948.2023.2183222.
   Web of Science ®Google Scholar
• AlBloushi AF, AlEnezi SH, Al Owaifeer AM, Al-Hadlaq OS, Gikandi PW, Abu El-Asrar AM. Long-term outcomes of uveitis associated with Vogt-Koyanagi-Harada disease in the pediatric age group. Ocul Immunol Inflamm. 2022;30(7–8):1669–1677. doi:10.1080/09273948.2021.1933074.
   PubMed Web of Science ®Google Scholar
• Sadhu S, Dutta Majumder P, Shah M, George R. Vogt-Koyanagi-Harada disease in pre-school children. Ocul Immunol Inflamm. 2022;32(4):415–418. doi:10.1080/09273948.2022.2117707.
   Google Scholar
• Hassan LC, Hassan MM, Abou Shady H, Khedr D. VKH with APECED in a two-year-old child: a rare concomitant diagnosis in an unprecedented age. Ocul Immunol Inflamm. 2023;32(4):433–436. doi:10.1080/09273948.2023.2208212.
   Web of Science ®Google Scholar
• Tobaigy MF, AlBloushi AF, Al-Dhibi HA. Reversal of peripheral iris depigmentation associated with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2023;32(4):424–428. doi:10.1080/09273948.2022.2161917.
   Web of Science ®Google Scholar